Effects of meloxicam on vascular endothelial growth factor and angiopoietin-2 expression in colon carcinoma cell line HT-29

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 27, Issue 4, 2007, Pages 399-402

  Zhang, Ning ^a   Tao, Kaixiong ^a   Huang, Tao ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Angiopoietin 2; Colon carcinoma cell line; Meloxicam; Vascular endothelial growth factor

Indexed keywords

ANGIOPOIETIN 2; CYCLOOXYGENASE 2 INHIBITOR; MELOXICAM; MESSENGER RNA; THIAZINE DERIVATIVE; THIAZOLE DERIVATIVE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; CELL STRAIN HT29; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; HT 29 CELL LINE;

ANGIOPOIETIN-2; CYCLOOXYGENASE 2 INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; RNA, MESSENGER; THIAZINES; THIAZOLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34548533057     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-007-0412-7     Document Type: Article

References (16)

1. McColl B K, Baldwin M E, Roufail S et al. Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D. J Exp Med, 2003,198:863-868
2. Poltorak Z, Cohen T, Sivan R et al. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem, 1997,272:7151-7158
3. Saito M, Hamasaki M, Shibuya M. Induction of tube formation by angiopoietin-1 in endothelial cell/fibroblast co-culture is dependent on endogenous VEGF. Cancer Sci 2003, 94990: 782-790
4. Thurston G, Suri C, Smith K et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science, 1999,286:2511-2514
5. Thruston G, Rudge J S, Ioffe E et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med, 2000,6:460-463
6. Ahmad S A, Liu W, Jung Y D et al. Differential expression of angiopoietin-1 and angiopoietin-2 in colon carcinoma. A possible mechanism for the initiation of angiogenesis. Cancer, 2001; 92:1138-1143
7. Holash J, Maisonpierre P C, Compton D et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science, 1999,284:1994-1998
8. Holash J, Wiegand S J, Yancopoulos G D. New model of tumor angiogensis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene,1999,18:5356-5362
9. Lobov I B, Brooks P C, Lang R A. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA, 2002, 99:11 205-11210
10. Smith T J. Cyclooxygenase as the principal targets for the actions of NASAIDs. Rheum Dis Clin Nor Am, 1998,24:501-523
11. Sinicrope F A, Gill S. Role of cyclooxygenase-2 in colorectal cancer.Cancer Metastasis Rev, 2004,23:63-75
12. Oshima M, Dinchuk J E, Karman S L et al. Suppression of intestinal polyposis in Apc delta 716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell, 1996,87:803-809
13. Seno H, Oshima M, Ishikawa T O et al. Cyclooxygenase-2 and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc (Delta716) mouse intestinal polyps. Cancer Res, 2002,62:506-511
14. Tomozawa S, Tsuno N H, Sunami E et al. Cyclooxygenase-2 overexpression correlates with tumor recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer, 2000,83:324-328
15. Williams C S, Tsujii M, Reese J et al. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest, 2000,105:1589-1594
16. Dempke W, Rie C, Grothey A et al. Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol, 2001,127:411-417